Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Iscalimab normalizes thyroid hormone levels in subset of Graves disease patients
Key clinical point: About half of patients with Graves disease saw normalization of thyroid hormone levels after 12 weeks of iscalimab treatment.
Major finding: Of 15 patients with Graves disease, 7 saw thyroid hormone levels normalize after 12 weeks; those with lower thyroid volume were more likely to see benefit (P less than .001).
Study details: Single-arm, open-label, multicenter, proof-of-concept study of 15 patients.
Disclosures: The study was sponsored by Novartis, which is developing iscalimab.
Citation:
Kahaly G et al. ATA 2019, Oral Presentation 23.